Department of Medical Oncology, Apollo Proton Cancer Centre, Chennai, India.
Department of Gastrointestinal & Hepato-Pancreato-biliary Service, Tata Memorial Centre, Mumbai, Maharashtra, India.
Indian J Med Res. 2020 Nov;152(5):468-474. doi: 10.4103/ijmr.IJMR_404_20.
This document aims to assist oncologists in making clinical decisions encountered while managing their patients with hepatocellular carcinoma (HCC), specific to Indian practice, based on consensus among experts. Most patients are staged by Barcelona Clinic Liver Cancer (BCLC) staging system which comprises patient performance status, Child-Pugh status, number and size of nodules, portal vein invasion and metastasis. Patients should receive multidisciplinary care. Surgical resection and transplant forms the mainstay of curative treatment. Ablative techniques are used for small tumours (<3 cm) in patients who are not candidates for surgical resection (Child B and C). Patients with advanced (HCC should be assessed on an individual basis to determine whether targeted therapy, interventional radiology procedures or best supportive care should be provided. In advanced HCC, immunotherapy, newer targeted therapies and modern radiation therapy have shown promising results. Patients should be offered regular surveillance after completion of curative resection or treatment of advanced disease.
本文件旨在根据专家共识,协助肿瘤科医生在管理肝细胞癌 (HCC) 患者时做出临床决策,具体针对印度的实际情况。大多数患者根据巴塞罗那临床肝癌 (BCLC) 分期系统进行分期,该系统包括患者的体能状态、Child-Pugh 状态、结节数量和大小、门静脉侵犯和转移。患者应接受多学科治疗。手术切除和移植是根治性治疗的主要方法。对于不适合手术切除的患者(Child B 和 C),消融技术适用于小肿瘤 (<3 cm)。对于晚期 (HCC 患者,应根据个体情况评估是否应提供靶向治疗、介入放射学治疗或最佳支持治疗。在晚期 HCC 中,免疫疗法、新型靶向治疗和现代放射治疗已显示出有前途的结果。根治性切除或晚期疾病治疗完成后,应定期对患者进行监测。